Company intelligence / Profile preview

Prothelia

Milford, Massachusetts, United Statesprothelia.golins.com ↗

Ownership: Private
Development stage: Preclinical

Overview

As of 2025, Prothelia's lead candidate recombinant human Laminin-111 (rhLAM-111) is in preclinical development. The company has made progress in manufacturing the protein and is conducting pre-clinical studies to establish safe and effective dosing. Natural history studies are being conducted in collaboration with various organizations to establish clinical outcomes for future trials[2][4].

Therapeutic areas: Rare Diseases
Modalities: Recombinant protein
Industry: Biotech

Drug pipeline

1 asset

human laminin-111

Preclinical

Partnerships

Alexion PharmaceuticalsUniversity of Nevada

Beyond the preview

Go deeper on Prothelia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prothelia.

Explore the full profile